Clinical trials: Pancreatic Cancer, Resected
Renal Cell Carcinoma, Metastases, Neoplasm
Surgical Treatment of Pancreatic RCC Metastases
Data from 26 patients undergoing resection of Pancreatic Metastases and extra-Pancreatic Metastases from RCC were retrospectively analysed.
- Trial name
- NCT03670992
- Testing
- duodenal-pancreatectomy
- Where
- Italy
- Volunteers
- 26 people
- Sponsor
- Azienda Policlinico Umberto I
Neoplasms, Cystic Fibrosis
PREMO Study: to Investigate Port REMoval Outcomes
A Totally Implantable Venous Access Device (TIVAD) that is no longer in use for intravenous therapy, should be flushed at established intervals to promote and maintain patency.
- Trial name
- PREMO (NCT03948958)
- Testing
- Evaluation of the catheter function, Catheter tip location, thrombus, sleeve and device damage visualization, Catheter-related colonization
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Universitaire Ziekenhuizen KU Leuven
Pancreatic Cancer
Resection in Pancreatic Cancer With Minimal Metastatic Disease or Venous Infiltration Trial at Technische Universität München
PaMeViTUM is a mono-centric prospective randomized controlled trial that compares different operating procedures in patients with pancreatic cancer and minimal metastatic disease or venous infiltration.
- Trial name
- PaMeViTUM (NCT00855634)
- Testing
- Resection of metastases, Resection of infiltrated veins
- Where
- Germany
- Volunteers
- 355 people
- Sponsor
- Technical University of Munich
Pancreatic Cancer
Prognostic Value of Baseline Computed Tomography (CT) Perfusion Parameters of Pancreatic Cancer for Patients Undergoing Stereotactic Body Radiotherapy or Surgical Resection
The purpose of this study is first, to determine whether baseline perfusion characteristics of pancreatic cancer, as characterized by CT perfusion studies, can predict tumor response to treatment by stereotactic body radiotherapy…
- Trial name
- NCT01326364
- Testing
- Stereotactic body radiotherapy, Iodixanol, Iohexol
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Stanford University
Pancreatic Cancer
Fluorouracil, Gemcitabine, and Radiation Therapy in Treating Patients With Cancer of the Pancreas
RATIONALE: Drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. Radiation therapy uses high-energy x-rays to damage tumor cells.
- Trial name
- NCT00003216
- Testing
- fluorouracil, gemcitabine hydrochloride, radiation therapy
- Where
- 107 sites in United States, Canada
- Volunteers
- 518 people
- Sponsor
- Radiation Therapy Oncology Group
Tumor of Pancreas
Evaluation of the Results of Simultaneous Pancreatic and Hepatic Resections for Metastatic Neuroendocrine Tumors.
The indications for synchronous liver resection for metastatic neuroendocrine tumors of pancreatic origin remain debated and poorly described in the literature.
- Trial name
- ReSiPaTNE (NCT05528614)
- Where
- France
- Volunteers
- 51 people
- Sponsor
- University Hospital, Strasbourg, France
Prehabilitation, Pancreas Cancer
Preoperative Optimisation of Modifiable Risk Factors in Surgery of the Pancreas
The goal of this stepped-wedge randomized controlled trial is to investigate whether implementation of a best practice program for preoperative optimisation (prehabilitation program) with a focus on screening, assessment, and…
- Conditions
- Prehabilitation, Pancreas Cancer, Surgery, Postoperative Complications
- Trial name
- PROMISE-P (NCT05851534)
- Testing
- Preoperative optimisation program
- Where
- 13 sites in Netherlands
- Volunteers
- 2,575 people
- Sponsor
- Maastricht University Medical Center
Resectable Pancreatic Adenocarcinoma
Gene Expression Profile of Resected Pancreatic and Ampullary Adenocarcinoma at Favorable Prognosis
The study aims at evaluating spatially resolved gene expression profiles of pancreatic and ampullary adenocarcinoma at favorable prognosis after surgical resection, in order to identify molecular features associated to a less…
- Trial name
- NCT05754788
- Where
- Italy
- Volunteers
- 40 people
- Sponsor
- Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Pancreatic Cancer
XH001 Combination With Immunocheckpoint Inhibitor and Chemotherapy for Patients With Resected Pancreatic Cancer
This is a single-center, open label, single-arm, investigator-initiated study to evaluate the efficacy and safety of XH001 (neoantigen cancer vaccine) sequential combination with immunocheckpoint inhibitor and chemotherapy in…
- Trial name
- NCT06353646
- Testing
- XH001, Ipilimumab Injection, Sintilimab injection
- Where
- China
- Volunteers
- 28 people
- Sponsor
- Wu Wenming
Pancreatic Cancer, Postoperative Adjuvant Therapy
Maintenance Chemotherapy With S-1 vs. Observation After Adjuvant Therapy for Resected Pancreatic Cancer With High Risk of Recurrence/Metastasis
The goal of this real-world study is to learn if maintenance chemotherapy with Tegafur, Gimeracil, and Oteracil Potassium (S-1) can improve disease-free survival (DFS) compared to follow-up observation in patients with resected…
- Conditions
- Pancreatic Cancer, Postoperative Adjuvant Therapy, Maintenance Therapy
- Trial name
- NCT06779318
- Testing
- S-1
- Where
- China
- Volunteers
- 464 people
- Sponsor
- The First Affiliated Hospital with Nanjing Medical University
Preoperative Physical Exercise Training, Aerobic Capacity
Home-based Prehabilitation in Pancreatic Resection
Rationale: The complication rate after pancreatic resection is high, especially in elderly and physically unfit patients. Aerobic capacity, as indicated by the ventilatory anaerobic threshold (VAT) assessed by a cardiopulmonary…
- Conditions
- Preoperative Physical Exercise Training, Aerobic Capacity, Aerobic Fitness, Functional Mobility
- Trial name
- NCT05496777
- Testing
- Home-based prehabilitation program
- Where
- 3 sites in Italy, Netherlands
- Volunteers
- 45 people
- Sponsor
- Nicole Hildebrand
Pancreatic Cancer
Italian Multicenter Study Comparing FOLFOXIRI Versus Gemcitabine as Adjuvant Treatment for Resected Pancreatic Cancer
Patients with resected pancreatic cancer who fulfill the selection criteria will be randomized to receive one of the two treatment arms for a period of 6 months: Gemcitabine, the standard arm, or FOLFOXIRI (the combination of…
- Trial name
- GIP-2 (NCT02355119)
- Testing
- FOLFOXIRI, Gemcitabine
- Where
- Italy
- Volunteers
- 310 people
- Sponsor
- Azienda Ospedaliero, Universitaria Pisana
Pancreatic Cancer
Low Dose Vaccine Study for Surgically Resected Pancreatic Cancer
To assess the response for subjects with pancreatic cancer that have undergone surgical resection and treatment with a vaccine given with or without chemotherapy and chemoradiation.
- Trial name
- NCT00614601
- Testing
- HyperAcute(R)-Pancreatic Cancer Vaccine
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- NewLink Genetics Corporation
Pancreas Cancer
Pancreatic Cancer & Surgical Resection
Primary Objective(s) To collect clinical data related to the treatment outcomes of Pancreatic IRE in order to develop an evidence base such that physicians can provide the best possible care to patients with pancreatic cancer…
- Trial name
- NCT05170802
- Testing
- NanoKnife procedure
- Where
- United States
- Volunteers
- 30 people
- Sponsor
- Methodist Health System
Pancreatic Fistula
Indocyanine Green Fluorescence in Evaluation of Pancreatic Remnant Perfusion.
Main goal of this study is to evaluate the blood flow in a post resection pancreatic remnant after pancreaticoduodenectomy with use of indocyanine green fluorescence.
- Trial name
- NCT06198400
- Testing
- Perioperative assessment of the perfusion of post-resection pancreatic remnant using indocyanine green-VerDye
- Where
- Czechia
- Volunteers
- 60 people
- Sponsor
- Charles University, Czech Republic
Pancreatic Cancer, Adjuvant Therapy
Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy as an Adjuvant Therapy for Pancreatic Cancer
The aim of this single center, single arm and prospective study is to explore the safety and efficacy of Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy in postoperative adjuvant treatment of Pancreatic Cancer
- Trial name
- NCT06344156
- Testing
- Neoantigen Vaccine Plus Anti-PD1 and Chemotherapy
- Where
- China
- Volunteers
- 43 people
- Sponsor
- Sichuan University
Pancreatic Head Cancer Patients Who Underwent Surgery After Neoadjuvant Treatment
Clinical Outcomes of Preservation Versus Resection of Portal/Superior Mesenteric Vein During Pancreaticoduodenectomy in Pancreatic Cancer Patients Who Respond to Neoadjuvant Treatment
1. There is a lack of evidence on the need to perform portal/superior mesenteric vein (PV/SMV) resection routinely in pancreatic ductal adenocarcinoma (PDAC) patients with venous involvement who responded to neoadjuvant treatment…
- Trial name
- NCT06372886
- Testing
- portal/superior vein resection
- Volunteers
- 264 people
- Sponsor
- Seoul National University Hospital
Pancreas Cancer
Safety and Efficacy of the Therapeutic Vaccine GI-4000 in Combination With Gemcitabine Versus Placebo for the Treatment of Non-metastatic, Post-resection Pancreas Cancer
The GI-4000 therapeutic vaccine or placebo will be injected under the skin of post-resection, non-metastatic pancreas cancer patients.
- Trial name
- NCT00300950
- Testing
- GI-4000, Gemcitabine
- Where
- 28 sites in United States, India
- Volunteers
- 176 people
- Sponsor
- GlobeImmune
Adenocarcinomas of the Pancreas
Study on Hyperthermic Intraperitoneal Chemotherapy After Resection of Pancreascarcinoma
In patients with peritoneal metastases of colorectal cancer could be a radical removal of all tumor foci a significantly improved survival compared to a sole systemic chemotherapy are additionally achieved by a hyperthermic…
- Trial name
- PanHIPEC (NCT02863471)
- Testing
- Gemcitabine
- Where
- Germany
- Volunteers
- 16 people
- Sponsor
- University Hospital Tuebingen
Pancreatic Neoplasms, Pancreatic Cancer
Gemcitabine/Cisplatin for Resected Pancreas Cancer: Establishing the Role of ERCC1 in Treatment Decision
The purpose of this study is to investigate if the investigators can use a specific marker in the pancreatic tumor itself to determine which patients will benefit from receiving combination chemotherapy of gemcitabine and…
- Trial name
- NCT01188109
- Testing
- Gemcitabine, Cisplatin
- Where
- 2 sites in United States
- Volunteers
- 25 people
- Sponsor
- Emory University